United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - midostaurin - capsule - 25mg

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - midostaurin - capsule, liquid filled - midostaurin 25mg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - belantamab mafodotin - powder for concentrate for solution for infusion - belantamab mafodotin 100 mg - belantamab - blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-cd38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - midostaurin 25 mg/cap - 25 mg/cap

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - midostaurin 25 mg/cap - 25 mg/cap

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis europharm limited, united kingdom - midostaurin - capsule, soft - 25 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - midostaurin 25mg - soft gelatin capsule - 25 mg - active: midostaurin 25mg excipient: corn oil, ethoxylated dl-alpha tocopherol ethanol gelatin glycerol iron oxide red iron oxide yellow macrogol 400 peg-40 castor oil purified water red printing ink (catalent) titanium dioxide - rydapt® is indicated: · in combination with standard anthracycline and cytarabine induction and cytarabine consolidation chemotherapy, followed in patients in complete response by single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive · for the treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated haematological neoplasms (sm-ahn), or mast cell leukaemia (mcl).